The global Virus Like Particles market was valued at US$ million in 2020 and is expected to reach US$ million by the end of 2027, growing at a CAGR of % during 2021-2027.
This report focuses on Virus Like Particles volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Virus Like Particles market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Virus Like Particles Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Adeno-Associated Virus
HIV
Hepatitis B Virus
Hepatitis C Virus
Others

Segment by Application
Vaccines
Mycoviruses
Virus Research
Therapeutic and Imaging Agents
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
GlaxoSmithKline
Merck
Novavax
Takeda
Medicago
MedImmune
TechnoVax
Agilvax
Allergy Therapeutics
Serum Institute of India
GeoVax Labs
Cytos Biotechnology
ANGANY Genetics
CPL Biologicals
Xiamen Innovax Biotech